logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Thomas J. Ettrich

Ulm University Medical Center
H指数:35
被引数:4,608

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

血浆PlGF作为Ramucirumab为基础的二线疗法治疗晚期胃食管腺癌的潜在生物标志物：RAMIRIS试验II期部分的探索性生物标志物分析

International Journal of Cancer
IF4.7
2026-08-150
OAAI
Jurek Hille; Sylvie Lorenzen; Claudia Pauligk; Victoria Gensch; Peter Thuss-Patience; Eray Goekkurt; Thomas Ettrich; Florian Lordick; Carsten Bokemeyer; Christian Müller; Peter Reichardt; Martin Sökler; Daniel Pink; Stefan Probst; Thorsten O. Goetze; Salah E. Al-Batran; Sonja Loges; Melanie Janning
Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer – the randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629)

阿柏西普和5-FU对比FOLFOX作为老年或虚弱老年患者转移性结直肠癌的一线治疗方案——随机II期AIO / IKF ELDERLY试验（AIO-KRK-0117 / IKF 629）。

European Journal of Cancer
IF7.1
2026-03-240
PRE
Ralf-Dieter Hofheinz; Ludwig Fischer von Weikersthal; Tobias Dechow; Reinhard Depenbusch; Christian Müller; Thorsten O. Goetze; Silvan Becker; Alexander Kiani; Thomas Ettrich; Alexander Schmittel; Holger Schulz; Matthias Ebert; Disorn Sookthai; Claudia Volk; Claudia Pauligk; Maria Loose; Salah-Eddin Al-Batran; Sylvie Lorenzen
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial

一线改良FOLFOX联合或不联合纳武利尤单抗和伊匹木单抗，或FLOT联合纳武利尤单抗用于晚期胃食管腺癌：一项多队列II期试验

Nature Communications
IF15.7
2026-02-270
OAAI
Sylvie Lorenzen; Thorsten Oliver Goetze; Peter C. Thuss-Patience; Jorge Riera-Knorrenschild; Eray Goekkurt; Tobias Nicolaas Dechow; Thomas Jens Ettrich; Ralf Dieter Hofheinz; Kim Barbara Luley; Daniel Pink; Udo Lindig; Gunnar Folprecht; Gunter Schuch; Michael Bitzer; Volker Heinemann; Stefan Angermeier; Claus Bolling; Maria Loose; Sabine Junge; Claudia Pauligk; Salah-Eddin Al-Batran
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial

围手术期帕博利珠单抗、曲妥珠单抗及FLOT方案在HER2阳性局限性食管胃腺癌中的疗效：一项Ⅱ期临床试验

Nature Medicine
IF50
2025-10-180
OAAI
Alexander Stein; Eray Goekkurt; Salah-Eddin Al-Batran; Nicolas Moosmann; Thomas J. Ettrich; Thorsten Goetze; Barbara Gruen; Nils Homann; Sylvie Lorenzen; Ralf-Dieter Hofheinz; Viktor Rempel; Gabriele Siegler; Christian Müller; Benjamin Thiele; Tobias Broering; Mariana Santos Cruz; Claudia Pauligk; Mascha Binder; Joseph Tintelnot
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)

预测性标准：晚期胰腺腺癌患者二线化疗的总体生存期和治疗持续时间（AIO-PAK-0216）

British Journal of Cancer
IF6.8
2025-10-140
OA
Manfred P. Lutz; Nikolaus Ansorge; Gleb Barmashenko; Hans Bauer; Christof Burkart; Thomas Decker; Thomas Ettrich; Ludwig Fischer von Weikersthal; Thomas Geer; Anke Gerhardt; Sabine Höfling; Lutz Jacobasch; Michael Koenigsmann; Tobias Leidig; Ruben Plentz; Sebastian Räth; Dietmar Reichert; Markos Schulte; Nadine Schulte; Andreas Schwarzer; Gabriele Siegler; Dirk Waldschmidt; Meinolf Karthaus
Interest in complementary and alternative medicine among participants in a study on cancer prevention by green tea extract – results from an expert-based survey of MIRACLE trial participants

关于绿茶提取物癌症预防研究中参与者对补充与替代医学的兴趣——来自MIRACLE试验参与者基于专家的调查结果

BMC Complementary Medicine and Therapies
IF3.4
2025-10-030
OA
Anna Melzer; Niklas Sturm; Friederike Rohlmann; Rainer Muche; Julia Stingl; Thomas J. Ettrich; Thomas Seufferlein
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

方案：粪菌移植在肝癌中克服阿替利珠单抗/贝伐珠单抗耐药的多中心、随机、安慰剂对照、双盲II期试验（FLORA试验）

BMJ OPEN
IF2.3
2025-09-090
OAAI
Rauber, Conrad; Roberti, Maria Paula; Vehreschild, Maria J. G. T.; Tsakmaklis, Anastasia; Springfeld, Christoph; Teufel, Andreas; Ettrich, Thomas; Jochheim, Leonie; Kandulski, Arne; Missios, Pavlos; Mohr, Raphael; Reichart, Alexander; Waldschmidt, Dirk T.; Sauer, Lukas D.; Sander, Anja; Schirmacher, Peter; Jaeger, Dirk; Michl, Patrick; Dill, Michael T.
Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study

伊沃西登ib治疗IDH1突变型肝内胆管癌：一项多中心真实世界研究的见解

Liver International
IF5.2
2025-08-260
OAAI
Monica Niger; Margherita Rimini; Florian Castet; Anna Melzer; Mario Domenico Rizzato; Tiziana Pressiani; Daniele Lavacchi; Giuseppe Aprile; Torsello Angela; Tiziana Saladino; Noventa Silvia; Pasqua Cito; Alessandro Pastorino; Eduardo Terán-Brage; Carolina Sciortino; Silvia Camera; Chiara Pircher; Mara Persano; Vincenzo Mazzaferro; Silvia Foti; Kreina Sharela Vega; Thomas J. Ettrich; Lorenzo Antonuzzo; Lorenza Rimassa; Sara Lonardi; Lukas Perkhofer; Teresa Macarulla; Filippo Pietrantonio; Andrea Casadei-Gardini
Impact of preoperative radiotherapy on patient-reported outcomes in rectal cancer

术前放疗对直肠癌患者报告结局的影响

Colorectal Disease
IF2.7
2025-07-100
PRE
Robert Siegel; Nora Tabea Sibert; Clara Breidenbach; Cihan Gani; Philipp Alexander Neumann; Stefan Rolf Benz; Stefan Post; Thomas Seufferlein; Vanessa Kolb; Matthias Behrend; Richard David Blossey; Jörg Bunse; Marc Dahlke; Ricarda Diller; Nikos Emmanouilidis; Thomas J. Ettrich; Jörg Fahlke; Sven Flemming; Björn Freitag; Martin Fuchs; Lars Haeder; Stephan Hollerbach; Jens Höppner; Mia Kim; Christian Klink; Jürgen Knuth; Stefan Koeppen; Jörg Köninger; Ernst Wolfgang Kolbe; Florian Kühn; Shueb Mussa; Robert Oehring; Sebastian Petzoldt; Pompiliu Piso; Christian Prause; Christian Prinz; Christoph Reißfelder; Maren Riechmann; Jörg-Peter Ritz; Jens Rolinger; Robert Rosenberg; Hubert Scheuerlein; Dustin Schilawa; Paul Magnus Schneider; Thilo Schwandner; Marco Siech; Daniel Steinemann; Oliver Stöltzing; Elke von Haeften; Dominik Weihs; Armin Wiegering; Christina Barbara Zielinski; Christoph Kowalski
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) (vol 7, 100552, 2024)
ESMO OPEN
IF8.3
2024-10-010
OAAI
Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Alguel, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V.; Kunzmann, V.
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
LANCET GASTROENTEROLOGY & HEPATOLOGY
IF38.6
2024-10-011
PRE
Dorman, Klara; Boeck, Stefan; Caca, Karel; Reichert, Maximilian; Ettrich, Thomas J.; Oettle, Helmut; Waidmann, Oliver; Modest, Dominik P.; Mueller, Lothar; Michl, Patrick; Kanzler, Stephan; Pink, Daniel; Reinacher-Schick, Anke; Geissler, Michael; Pelz, Henning; Kunzmann, Volker; Held, Swantje; Schichtl, Thomas; Heinemann, Volker; Kullmann, Frank
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial

改良FOLFOX联合或不联合纳武利尤单抗和伊匹木单抗对比FLOT联合纳武利尤单抗治疗既往未接受治疗的胃或胃食管结合部腺癌晚期或转移性患者的最终结果：IKF-AIO-Moonlight试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-012
PRE
Lorenzen, S.; Goetze, T. O.; Thuss-Patience, P. C.; Knorrenschild, J. Riera; Goekkurt, E.; Dechow, T. N.; Ettrich, T. J.; Hofheinz, R. D.; Luley, K.; Pink, D.; Lindig, U.; Folprecht, G.; Schuch, G.; Bitzer, M.; Heinemann, V.; Angermeier, S.; Bolling, C.; Junge, S.; Pauligk, C.; Al-Batran, S-E.
Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial

PIK3CA突变结直肠癌患者的辅助阿司匹林治疗：SAKK 41/13 III期、前瞻性随机安慰剂对照多中心试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-013
PRE
Guller, U.; Hayoz, S.; Horber, D.; De Dosso, S.; Koeberle, D.; Kaufmann, S. Schacher; Inauen, R. I.; Stahl, M.; Delaunoit, T.; Ettrich, T. J.; Bodoky, G. M.; Michel, P.; Kossler, T.; Rothgiesser, K.; Calmonte, S.; Joerger, M.
Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)

NEONAX试验的探索性生物标志物分析，用于预测可切除胰腺导管腺癌患者（rPDAC Pts）对围手术期（PO）和辅助性（A）Gem-nabPac化疗（CTX）的治疗反应

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Lahusen, A.; Ettrich, T. J.; Kirchner, M.; Kluck, K.; Wisser, S.; Uhl, W.; Kornmann, M.; Alguel, H.; Friess, H.; Koenig, A. O.; Kleger, A.; Schuhbaur, J.; Perkhofer, L.; Budczies, J.; Tempero, M. A.; Reinacher-Schick, A.; Stenzinger, A.; Tannapfel, A.; Eiseler, T.; Seufferlein, T.
Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study

Ramucirumab联合达卡巴嗪治疗进行性高分化转移性胰腺神经内分泌肿瘤 (RamuNET): 一项AIO II期多中心单臂研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Krug, S.; Apostolidis, L.; Koenig, A. O.; Rinke, A.; Schrader, J.; Ettrich, T. J.; Jann, H.; Oberbeck, M.; Hoersch, D.; Gress, T. M.; Kegel, T.; Richter, M.; Behl, S.; Steighardt, J.; Michl, P.
Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial

帕博利珠单抗和奥拉帕尼在HER2阴性晚期食道胃腺癌（EGA）中的研究：AIO IKF-038/POLESTAR II期试验的生物标志物结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Haag, G. M.; Goetze, T. O.; Thuss-Patience, P. C.; Knorrenschild, J. Riera; Lorenzen, S.; Homann, N.; Ettrich, T. J.; Walle, T.; Brobeil, A.; Ball, M.; Schaaf, M.; Tenekeci, U.; Pauligk, C.; Al-Batran, S-E.; Stenzinger, A.; Stein, A.
Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)

在重度预处理的转移性结直肠癌中，比较雷莫芦单抗联合TAS102（三氟尿苷/替吡拉塞）与TAS102单药治疗的随机III期试验：德国AIO（AIO-KRK-0316）的RAMTAS/IKF643试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Kasper-Virchow, S.; Hofheinz, R. D.; Stintzing, S.; Dechow, T. N.; Ettrich, T. J.; Sinn, M.; Roderburg, C.; von Weikersthal, L. Fischer; Graeven, U.; Mueller, C.; Meiler, J.; Stein, A.; Modest, D. P.; Pauligk, C.; Virchow, I.; Siveke, J. T.; Al-Batran, S-E.; Schuler, M. H. H.; Goetze, T. O.

研究方向

暂未获取到该数据
T
Thomas Seufferlein
H 指数:78论文数:868被引数:3.5万
S
Sylvie Lorenzen
H 指数:37论文数:379被引数:6,205
T
Thorsten Oliver Goetze
H 指数:29论文数:250被引数:7,797
C
Claudia Pauligk
H 指数:34论文数:253被引数:8,456
L
Lukas Perkhofer
H 指数:25论文数:253被引数:2,406
R
Ralf‐Dieter Hofheinz
H 指数:57论文数:606被引数:1.8万
G
Gabriele Margareta Siegler
H 指数:18论文数:55被引数:1,267
E
Eray Goekkurt
H 指数:30论文数:215被引数:9,441
D
Daniel Pink
H 指数:33论文数:238被引数:8,562
D
Dirk Waldschmidt
H 指数:25论文数:151被引数:3,742